Formulations of 5-fluorocytosine and uses thereof
The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
1. A gastro-retentive oral pharmaceutical composition comprising 5-fluorocytosine (5-FC), wherein the pharmaceutical composition is a monolithic solid tablet form comprising at least one hydrophilic matrix forming polymer of about 5 to 40 weight percent, hydroxypropyl cellulose (HPC) and microcrystalline cellulose (MCC) of about 5 to 30 weight percent, dicalcium phosphate of about 11 weight percent, magnesium stearate and opadry white and releases 5-FC into the upper gastrointestinal tract of a subject over a sustained period of time.
2. The pharmaceutical composition of claim 1 , wherein the weight ratio of 5-FC to the at least one hydrophilic polymer is about 5:1.
3. The pharmaceutical composition of claim 1 , wherein the weight ratio of the at least one hydrophilic polymer to HPC and MCC is about 1:2 to about 2:1.
4. The pharmaceutical composition of claim 1 , wherein the ratio of dicalcium phosphate to the at least one hydrophilic polymer is about 1:1.
5. The pharmaceutical composition of claim 2 , wherein the at least one hydrophilic matrix forming polymer is one or more of carbopol and/or kollidon.
6. The pharmaceutical composition of claim 3 , wherein the at least one hydrophilic matrix forming polymers make up about 8 weight percent to about 30 weight percent of the composition.
7. The pharmaceutical composition of claim 1 , wherein 5-FC is present in the composition at about 500 mg.
8. The pharmaceutical composition of claim 1 , wherein the composition exhibits 5-FC in vitro dissolution rate of greater than about 80% within about 4 to about 12 hours at pH 1.0 as measured by the USP Type II dissolution apparatus (paddle method) at 75 rpm at 37° C. using 5-FC USP method with UV detection at about 275 - 285 nm.
9. The pharmaceutical composition of claim 1 , wherein after a single dose oral administration to a fed subject the composition exhibits: (i) a t median of about 3 hrs or greater; (ii) a t max of about 3 hrs or greater; and (iii) a t 1/2 of between about 3-8 hrs.
10. The pharmaceutical composition of claim 1 , wherein 5-FC is present in the pharmaceutical composition in an amount of about 500 mg, after single oral administration of the 500 mg pharmaceutical composition to a fed subject, the composition exhibits one or more of the following: (i) a 5-FC C max of between about 2.0 μg/ml and about 10.0 μg/ml, (ii) a t max of about 3 hrs or greater; (iii) an AUC ∞ of about 20-80 μg*hr/ml; and (iv) a t 1/2 of between about 3-8 hrs.
11. The pharmaceutical composition of claim 1 , wherein following daily administration for about 7 days or about 5 half-lives or more with 1-250 mg/Kg/day in divided doses to a fed human subject the mean serum concentration of 5-FC during a 24 hour period is about 1-200 μg/ml.
12. The pharmaceutical composition of claim 11 , wherein following a repeated dose for 6 weeks with 1-250 mg/Kg/day in divided doses to a fed human subject the mean serum concentration of 5-FC during a 24 hour period is about 1-200 μg/ml.
13. The pharmaceutical composition of claim 11 , wherein following daily administration for 7 days or about 5 half-lives or more with 1-250 mg/Kg/day in divided doses to a fed human subject the mean serum concentration of 5-FC during a24 hour period is about 30-80 μg/ml.
14. The pharmaceutical composition of claim 1 , wherein the composition is administered 2-4 times per day.
15. A method of treating a fungal infection by administering a pharmaceutical composition according to claim 1 .
16. A method of treating cancer in a mammal by administering a pharmaceutical composition according to claim 1 in conjunction with a polypeptide comprising cytosine deaminase activity to treat cancer in a mammal.
17. A method of treating cancer in a mammal having previously received cytosine deaminase gene therapy comprising administering to the mammal a pharmaceutically effective amount of a composition of claim 1 .
18. The method of claim 17 , wherein the cytosine deaminase gene therapy comprises an oncoretroviral vector having an internal ribosome entry site operably linked to a polynucleotide encoding a polypeptide having cytosine deaminase activity.